健康状况

18 基于循证研究的健康状况与补充剂信息

Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.

How We Grade Evidence

每个健康状况页面按临床证据强度对补充剂成分进行排序。以下是各等级的含义：

Strong Evidence

Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.

Good Evidence

At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.

Some Evidence

Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.

Very Early Research

In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.

伤口愈合

Relevant to all individuals; chronic non-healing wounds affect 1-2% of the population in developed countries

Delayed wound closure Excessive scar formation Wound infection +2

妊娠纹

Affects 50-90% of pregnant women; common during adolescent growth spurts and rapid weight changes

Linear streaks on skin Initially red/purple (striae rubrae) Mature to white/silvery (striae albae) +2

日晒损伤与光老化

Virtually universal in adults with cumulative sun exposure; responsible for up to 90% of visible skin aging

Solar lentigines (sun spots) Deep wrinkles and leathery texture Solar elastosis +3

橘皮组织

Affects 80-90% of post-pubertal women; rare in men due to different connective tissue architecture

Dimpled or lumpy skin (orange-peel texture) Primarily on thighs, buttocks, and hips May worsen with age and weight gain +1

毛发、皮肤与指甲健康

One of the most popular supplement categories; hair/skin/nail supplement market exceeds $2 billion annually

Brittle nails Dull or thinning hair Dry or lackluster skin +3

毛周角化症

Affects 50-80% of adolescents and approximately 40% of adults

Small rough bumps on upper arms, thighs, cheeks, or buttocks Dry or sandpaper-like skin texture Mild redness around bumps +1

湿疹（特应性皮炎）

Affects 15-20% of children and 1-3% of adults worldwide

Intense itching (pruritus) Dry and scaly skin Red or inflamed patches +3

玫瑰痤疮

Affects 2-10% of the global population; more common in fair-skinned individuals

Persistent central facial erythema Flushing and blushing episodes Papules and pustules (without comedones) +3

痤疮

Affects approximately 85% of people aged 12-24; 12-22% of adult women experience acne

Comedones (blackheads, whiteheads) Papules and pustules Nodules and cysts (severe) +3

白癜风

Affects 0.5-2% of the global population

Well-defined white patches on skin Premature graying of hair Loss of color in oral mucosa +2

皮肤屏障功能

Impaired in multiple conditions: eczema, psoriasis, rosacea, aged skin, sensitive skin

Increased transepidermal water loss (TEWL) Sensitivity to irritants Stinging or burning with products +3

皮肤干燥

Affects approximately 29-85% of adults depending on climate, age, and definition used

Tight or rough skin texture Visible flaking or peeling Itching +3

皮肤老化与皱纹

Universal process; visible signs typically begin in late 20s to early 30s

Fine lines and wrinkles Loss of skin elasticity and firmness Thinning skin +4

眼部黑眼圈

Extremely common; a primary cosmetic complaint across all age groups and ethnicities

Dark discoloration under eyes Bluish or purplish tint (vascular) Brown pigmentation (melanin) +2

紫外线防护（内源性光防护）

Relevant to all individuals with sun exposure; growing consumer interest

Sunburn susceptibility Premature photoaging Actinic keratoses +2

胶原蛋白流失

Universal age-related process; accelerated in post-menopausal women

Loss of skin firmness and elasticity Increased wrinkle formation Skin thinning +3

色素沉着过度

Melasma affects 15-50% of pregnant women; PIH common in darker skin tones (Fitzpatrick IV-VI)

Dark patches on face (melasma: cheeks, forehead, upper lip) Dark spots at sites of prior acne or injury (PIH) Age spots (solar lentigines) +1

银屑病

Affects 2-3% of the global population; plaque psoriasis accounts for 80-90% of cases

Thick red plaques with silvery-white scales Itching and burning Nail changes (pitting, onycholysis) +2

FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。